[Controversies and future of the approach to cardiovascular disease in HIV patients]

Related Experiment Video

Updated: Jun 16, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

José Ignacio Bernardino de la Serna1, José Ramón Arribas López

  • 1Unidad VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, España. jibernardino.hulp@salud.madrid.org

Enfermedades Infecciosas Y Microbiologia Clinica
|February 23, 2010
PubMed

Insights

Cardiovascular disease is a growing concern for people with HIV infection. Risk assessment equations are crucial for identifying patients needing interventions, regardless of the primary cause.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Context:

  • Cardiovascular diseases (CVD) pose an increasing threat to patients with HIV infection.
  • The etiology of elevated CVD risk in HIV-infected individuals is multifactorial, involving traditional risk factors, the virus itself, and antiretroviral therapy.
  • The relative contribution of each factor to overall cardiovascular risk remains under investigation.

Purpose:

  • To explore the multifactorial causes of increased cardiovascular risk in HIV-infected patients.
  • To determine the most significant contributors to cardiovascular disease in this population.
  • To emphasize the need for integrated cardiovascular risk assessment in HIV care.

Summary:

  • Cardiovascular disease risk in HIV-infected patients is complex and multifactorial.
  • The exact weight of traditional risk factors, HIV, and antiretroviral therapy is not yet fully elucidated.
  • Individual patient risk is determined by a composite risk profile, necessitating routine use of cardiovascular risk equations.

Impact:

  • Highlights the need for standardized cardiovascular risk assessment in HIV-infected individuals.
  • Informing clinical practice to proactively manage cardiovascular health in this vulnerable population.
  • Guiding future research to precisely quantify risk factors in HIV-associated cardiovascular disease.

More Related Videos

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...